個人簡介：
中山大學(xué)附屬第七醫(yī)院副研究員,，碩士生導(dǎo)師，深圳市高層次人才,。主要研究方向：新型生物醫(yī)藥設(shè)計與抗腫瘤應(yīng)用及其腫瘤耐藥逆轉(zhuǎn)研究,。共發(fā)表論文20余篇，其中以第一/通訊作者發(fā)表研究論文16篇,，研究成果主要發(fā)表在Molecular Cancer,、Advanced Materials、Drug resistance updates,、Cancer Letters,、ACS Applied Materials & Interfaces、Inorganic Chemistry Frontiers,、Chemical Communications等期刊,，申請中國發(fā)明專利1項(xiàng)并獲得授權(quán)。目前主持國自然科學(xué)基金青年項(xiàng)目,、廣東省自然科學(xué)面上項(xiàng)目1項(xiàng),、深圳市醫(yī)學(xué)研究專項(xiàng)青年項(xiàng)目，深圳市面上項(xiàng)目2項(xiàng),，參與國自然科學(xué)基金面上項(xiàng)目1項(xiàng),。
?
教育背景：
2017/09-2020/06 中山大學(xué)??生物無機(jī)化學(xué) ??博士
2014/09-2017/06 湘潭大學(xué)??化學(xué)生物學(xué)?????碩士
?
工作經(jīng)歷：
2024/01-至今 ???中山大學(xué)，附屬第七醫(yī)院,，副研究員
2022/10-2023/12 中山大學(xué),，附屬第七醫(yī)院，助理研究員
2020/09-2022/09 中山大學(xué),，附屬第七醫(yī)院,，博士后
?
主要研究方向:
1. 新型抗腫瘤藥物設(shè)計與抗腫瘤應(yīng)用研究
2. 工程化外泌體構(gòu)建與腫瘤精準(zhǔn)治療研究
3. 微生物耐藥與腫瘤多藥耐藥逆轉(zhuǎn)研究
?
?
項(xiàng)目經(jīng)費(fèi)
(1)深圳市醫(yī)學(xué)研究專項(xiàng)資金管理委員會，青年項(xiàng)目,，2025-01至2027-12,，80萬元,在研,主持。
(2)深圳市科技創(chuàng)新委員會,，面上項(xiàng)目,，2024-10至2027-11，30萬元,在研,，主持,。
(3)國家自然科學(xué)基金委員會,，國家自然科學(xué)基金青年項(xiàng)目，2024-01至2026-12,，30萬元,，在研，主持,。
(4)國家自然科學(xué)基金委員會,，面上項(xiàng)目，2023-01至2026-12,，53萬元,，在研，參與,。
(5)廣東省基礎(chǔ)與應(yīng)用基礎(chǔ)研究基金委員會,，面上項(xiàng)目，2023-01至2025-12,，10萬元,，在研，主持,。
(6)深圳市科技創(chuàng)新委員會,，面上項(xiàng)目，2022-10至2025-10,，15萬元,，在研，主持,。
(7)廣東省消化系統(tǒng)惡性腫瘤防治研究重點(diǎn)實(shí)驗(yàn)室2022年度開放基金,，5萬元，結(jié)題,，主持,。
?
代表性論文?(1為第一/共同第一作者，*為通訊/共同通訊作者)
(1) Tsz Kin Mak1, Kuan Li1, Zidan Zhao1, Kexin Wang, Leli Zeng, Qilang He, Weiqun Lu, Wei Chen, Yulong He*, Jia Li*, Changhua Zhang*,?m6A demethylation of NNMT in CAFs promotes gastric cancer progression by enhancing macrophage M2 polarization, Cancer Letters, 2025, 611: 217422.?中科院一區(qū) (IF=9.1)
(2) Hongfa Wei1, Wenchao Li1, Leli Zeng, Ni Ding, Kuan Li, Hong Yu, Fei Jiang, Haofan Yin, Yu Xia, Cuncan Deng, Nan Cai, Xiancong Chen, Liang Gu, Huanjie Chen, Feiran Zhang*, Yulong He*, Jia Li*, Changhua Zhang*, OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3β/β-catenin pathway, Molecular Cancer, 2024, 23(1): 124. 中科院一區(qū) (IF=27.7)
(3) Cuncan Deng1,?Mingyu Huo1,?Hongwu Chu1,?Xiaomei Zhuang1,?Guofei Deng, Wenchao Li,?Hongfa Wei,?Leli Zeng*,?Yulong He,?Huashan Liu,?Jia Li*,?Changhua Zhang*,?Hengxing Chen*,?Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote
gastric cancer progression, Molecular Cancer, 2024, 23(1): 49. 中科院一區(qū) (IF=27.7)
(4) Jia Li, Zhe-Sheng Chen*, Yihang Pan*, Leli Zeng*. The important role of lactylation in regulating DNA damage repair and tumor chemotherapy resistance, Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy, 2024: 101148.?中科院一區(qū) (IF=15.8)
(5) Hengxing Chen1, Yun Li1, Huafu Li1, Xiancong Chen, Huafeng Fu, Deli Mao, Wei Chen, Linxiang Lan, Chunming Wang, Kaishun Hu, Jia Li, Chengming Zhu, Ian Evans, Eddie Cheung, Daning Lu, Yulong He*, Axel Behrens*, Dong Yin*, Changhua Zhang*, NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance, Nature, 2024, 631(8021): 663-669. 中科院一區(qū) (IF=50.5)
(6) Huan Yang, Yuhong Liu,?Jia Li*, Yulong He*, Leli Zeng*, Yihang Pan*,?The Role of Organoid‐Based Drug Sensitivity Testing in Clinical Cancer Therapy, Organ Medicine, 2024, 1(2): 49-50.
(7) Leli Zeng1, B. H. Jaswanth Gowda1, Mohammed Gulzar Ahmed, Mohammed A. S. Abourehab,?Zhe-Sheng Chen, Changhua Zhang*,?Jia Li*, Prashant Kesharwani*, Advancements in nanoparticle-based treatment approaches for skin cancer therapy, Molecular Cancer, 2023, 22(1):0-10. 中科院一區(qū)?(IF=27.7)
(8)?Jia Li1, Leli Zeng1*, Zheng Wang, Hengxing Chen, Shuo Fang, Jinquan Wang, Chao-Yun Cai, Enming Xing, Xinxing Liao, Zhi-Wei Li, Charles R. Ashby Jr, Zhe-Sheng Chen*, Hui Chao*, Yihang Pan*, Cycloruthenated Self-Assembly with Metabolic Inhibition to Efficiently?Overcome Multidrug Resistance in Cancers, Advanced Materials, 2022, 34(1): 0-2100245.?中科院一區(qū)?(IF=27.4)
(9) Johannes Karges1, Jia Li1, Leli Zeng, Hui Chao*, Gilles Gasser*, Polymeric Encapsulation of a Ruthenium Polypyridine Complex for Tumor Targeted One- and Two-Photon?Photodynamic Therapy, ACS Applied Materials & Interfaces, 2020, 12(49): 54433-54444.?中科院一區(qū)?(IF=8.5)
(10) Jia Li, Hongmin Chen, Leli Zeng, Thomas W. Rees, Kai Xiong, Yu Chen*, Liangnian Ji, Hui Chao*, Mitochondria- targeting cyclometalated iridium(III) complexes for tumor?hypoxic imaging and therapy, Inorganic Chemistry Frontiers, 2019, 6(4): 1003-1010.?中科院一區(qū)?(IF=6.1)
(11) Jia Li, Leli Zeng, Kai Xiong, Thomas W. Rees, Chengzhi Jin, Weijun Wu, Yu Chen*, Liangnian Ji, Hui Chao*, A biotinylated ruthenium(ii) photosensitizer for tumor-targeted twophoton photodynamic therapy, Chemical Communications, 2019, 55(73): 10972-10975.?中科院二區(qū)?(IF=4.3)
(12) Leli Zeng?1, Jia Li?1, Chen Zhang, Yun-Kai Zhang, Wei Zhang, Juanjuan Huang, Charles R. Ashby Jr, Zhe-Sheng Chen*, Hui Chao*, An organoruthenium complex overcomes ABCG2- mediated multidrug resistance via multiple mechanisms, Chemical Communications, 2019, 55(26):?3833-3836.?中科院二區(qū)(IF=4.3)
個人郵箱:
lijia[email protected]